{'fraction_non_alphanumeric': 0.04294478527607362, 'fraction_numerical': 0.022494887525562373, 'mean_word_length': 5.621621621621622, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Fas‐Fas ligand signaling pathway mediates an interleukin‐12–induced rejection of a murine prostate tumor system

Recent data suggest that anti‐tumor activities of interleukin‐12 (IL‐12) involve the induction of apoptosis. Fas (APO‐1/CD95) is a type I membrane protein that is capable of initiating an apoptosis signaling pathway when bound to its ligand (FasL). We undertook this study to test the hypothesis that Fas‐FasL–mediated apoptosis plays a role in IL‐12–induced tumor regression.